Use of sibutramine analogues to prevent the development of diabetes
US6174925A · kind A · utility
14Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 1999 |
| Grant date | Jan 16, 2001 |
| Priority date | — |
| Expiry date | Mar 17, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.